{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:41:05Z","timestamp":1774791665511,"version":"3.50.1"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BALB\/c mice bearing syngeneic BCL1 leukemia, a mouse model of human chronic lymphocytic leukemia, were treated with polymer-bound doxorubicin conjugate targeted with BCL1-specific monoclonal antibody. Such treatment can cure up to 100% of mice and the cured mice show long-lasting resistance to BCL1 leukemia. We show that both CD4+ and CD8+ T cells are required for establishment of the resistance, but only CD8+ T cells are necessary for its maintenance. BCL1 cells express MHC class I and II and also costimulatory molecules CD80 and CD86, which can aid eliciting of antitumor response. On the other hand, BCL1 cells also use several immunoescape mechanisms, such as expression of PD-L1, PD-L2, and interleukin-10. BCL1 cells thus can be recognized by BCL1-specific T cells, but instead of effective priming, such T cells are anergized or deleted by apoptosis. Moreover, BCL1 leukemia progression is accompanied by robust expansion of CD4+CD25+Foxp3+ regulatory T (Treg) cells. Although it has been shown that depletion of Treg cells in tumor-bearing mice can retard tumor growth, direct evidence that expansion of Treg cells can promote tumor growth was lacking. In this study, we provide first direct evidence that expanded Treg cells can indeed promote tumor progression by using mice with selectively expanded Treg cells before inoculation of BCL1 leukemia. Finally, we have also shown that elimination of some immunoescape mechanism (e.g., deletion of Treg) can significantly improve the therapeutic outcome of chemotherapy. [Cancer Res 2008;68(23):9875\u201383]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-1979","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T08:38:24Z","timestamp":1228120704000},"page":"9875-9883","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell\u2013Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin"],"prefix":"10.1158","volume":"68","author":[{"given":"Marek","family":"Kovar","sequence":"first","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Tomala","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Chmelova","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Kovar","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Mrkvan","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radka","family":"Joskova","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Zakostelska","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Etrych","sequence":"additional","affiliation":[{"name":"2Laboratory of Biomedical Polymers, Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Strohalm","sequence":"additional","affiliation":[{"name":"2Laboratory of Biomedical Polymers, Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Ulbrich","sequence":"additional","affiliation":[{"name":"2Laboratory of Biomedical Polymers, Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milada","family":"Sirova","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanka","family":"Rihova","sequence":"additional","affiliation":[{"name":"1Department of Immunology and Gnotobiology, Institute of Microbiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,12,1]]},"reference":[{"key":"2022061700295934200_B1","doi-asserted-by":"crossref","unstructured":"Sirova M, Strohalm J, Subr V, et al. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol Immunother\u20082007; 56: 35\u201347.","DOI":"10.1007\/s00262-006-0168-0"},{"key":"2022061700295934200_B2","doi-asserted-by":"crossref","unstructured":"Kovar M, Mrkvan T, Strohalm J, et al. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J Control Release\u20082003; 92: 315\u201330.","DOI":"10.1016\/S0168-3659(03)00340-7"},{"key":"2022061700295934200_B3","doi-asserted-by":"crossref","unstructured":"Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature\u20081978; 272: 624\u20136.","DOI":"10.1038\/272624a0"},{"key":"2022061700295934200_B4","doi-asserted-by":"crossref","unstructured":"Rihova B, Strohalm J, Kovar M, et al. Induction of systemic antitumour resistance with targeted polymers. Scand J Immunol\u20082005; 62 Suppl 1: 100\u20135.","DOI":"10.1111\/j.1365-3083.2005.01617.x"},{"key":"2022061700295934200_B5","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000; 100: 57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061700295934200_B6","doi-asserted-by":"crossref","unstructured":"Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol\u20082006; 90: 1\u201350.","DOI":"10.1016\/S0065-2776(06)90001-7"},{"key":"2022061700295934200_B7","doi-asserted-by":"crossref","unstructured":"Burnet FM. The concept of immunologic surveillance. Prog Exp Tumor Res\u20081970; 13: 1\u201327.","DOI":"10.1159\/000386035"},{"key":"2022061700295934200_B8","doi-asserted-by":"crossref","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol\u20082004; 22: 329\u201360.","DOI":"10.1146\/annurev.immunol.22.012703.104803"},{"key":"2022061700295934200_B9","doi-asserted-by":"crossref","unstructured":"So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res\u20082005; 65: 5945\u201352.","DOI":"10.1158\/0008-5472.CAN-04-3787"},{"key":"2022061700295934200_B10","doi-asserted-by":"crossref","unstructured":"Atkins D, Breuckmann A, Schmahl GE, et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer\u20082004; 109: 265\u201373.","DOI":"10.1002\/ijc.11681"},{"key":"2022061700295934200_B11","doi-asserted-by":"crossref","unstructured":"Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A\u20082001; 98: 11515\u201320.","DOI":"10.1073\/pnas.201398198"},{"key":"2022061700295934200_B12","doi-asserted-by":"crossref","unstructured":"Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol\u20082005; 27: 19\u201335.","DOI":"10.1007\/s00281-004-0192-0"},{"key":"2022061700295934200_B13","doi-asserted-by":"crossref","unstructured":"Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol\u20082005; 5: 641\u201354.","DOI":"10.1038\/nri1668"},{"key":"2022061700295934200_B14","doi-asserted-by":"crossref","unstructured":"Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med\u20082003; 9: 1269\u201374.","DOI":"10.1038\/nm934"},{"key":"2022061700295934200_B15","doi-asserted-by":"crossref","unstructured":"Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med\u20082002; 196: 447\u201357.","DOI":"10.1084\/jem.20020052"},{"key":"2022061700295934200_B16","doi-asserted-by":"crossref","unstructured":"Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer\u20082005; 113: 78\u201387.","DOI":"10.1002\/ijc.20538"},{"key":"2022061700295934200_B17","doi-asserted-by":"crossref","unstructured":"Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer\u20082005; 5: 263\u201374.","DOI":"10.1038\/nrc1586"},{"key":"2022061700295934200_B18","unstructured":"Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol\u20082004; 22: 531\u201362."},{"key":"2022061700295934200_B19","doi-asserted-by":"crossref","unstructured":"Ulbrich K, Subr V, Strohalm J, Plocova D, Jelinkova M, Rihova B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release\u20082000; 64: 63\u201379.","DOI":"10.1016\/S0168-3659(99)00141-8"},{"key":"2022061700295934200_B20","doi-asserted-by":"crossref","unstructured":"Kovar M, Strohalm J, Etrych T, Ulbrich K, Rihova B. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem\u20082002; 13: 206\u201315.","DOI":"10.1021\/bc010063m"},{"key":"2022061700295934200_B21","doi-asserted-by":"crossref","unstructured":"Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science\u20082006; 311: 1924\u20137.","DOI":"10.1126\/science.1122927"},{"key":"2022061700295934200_B22","unstructured":"Weiss L, Reich S, Slavin S. Allogeneic cell therapy in murine B-cell leukemia (BCL1). 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Cytokines Cell Mol Ther\u20081999; 5: 153\u20138."},{"key":"2022061700295934200_B23","doi-asserted-by":"crossref","unstructured":"Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol\u20082007; 19: 309\u201314.","DOI":"10.1016\/j.coi.2007.04.012"},{"key":"2022061700295934200_B24","doi-asserted-by":"crossref","unstructured":"Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol\u20082007; 179: 5064\u201370.","DOI":"10.4049\/jimmunol.179.8.5064"},{"key":"2022061700295934200_B25","doi-asserted-by":"crossref","unstructured":"Bellinghausen I, Konig B, Bottcher I, Knop J, Saloga J. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-\u03b2 for their induction. Clin Exp Allergy\u20082006; 36: 1546\u201355.","DOI":"10.1111\/j.1365-2222.2006.02601.x"},{"key":"2022061700295934200_B26","doi-asserted-by":"crossref","unstructured":"Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol\u20082000; 30: 1683\u201390.","DOI":"10.1002\/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A"},{"key":"2022061700295934200_B27","doi-asserted-by":"crossref","unstructured":"Akdis CA, Joss A, Akdis M, Blaser K. Mechanism of IL-10-induced T cell inactivation in allergic inflammation and normal response to allergens. Int Arch Allergy Immunol\u20082001; 124: 180\u20132.","DOI":"10.1159\/000053704"},{"key":"2022061700295934200_B28","doi-asserted-by":"crossref","unstructured":"Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM, Mescher MF, Ingulli E. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J Immunol\u20082005; 174: 6909\u201317.","DOI":"10.4049\/jimmunol.174.11.6909"},{"key":"2022061700295934200_B29","doi-asserted-by":"crossref","unstructured":"Schmidt CS, Mescher MF. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol\u20082002; 168: 5521\u20139.","DOI":"10.4049\/jimmunol.168.11.5521"},{"key":"2022061700295934200_B30","doi-asserted-by":"crossref","unstructured":"Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol\u20082002; 169: 6842\u20139.","DOI":"10.4049\/jimmunol.169.12.6842"},{"key":"2022061700295934200_B31","doi-asserted-by":"crossref","unstructured":"Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol\u20082005; 174: 600\u20134.","DOI":"10.4049\/jimmunol.174.2.600"},{"key":"2022061700295934200_B32","doi-asserted-by":"crossref","unstructured":"Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-\u03b2 or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol\u20082003; 74: 471\u20138.","DOI":"10.1189\/jlb.0503228"},{"key":"2022061700295934200_B33","doi-asserted-by":"crossref","unstructured":"Martens E, Alloza I, Scott CJ, Billiau A, Vandenbroeck K. Protein disulfide isomerase-mediated cell-free assembly of recombinant interleukin-12 p40 homodimers. Eur J Biochem\u20082000; 267: 6679\u201383.","DOI":"10.1046\/j.1432-1327.2000.01765.x"},{"key":"2022061700295934200_B34","doi-asserted-by":"crossref","unstructured":"Stallmach A, Marth T, Weiss B, et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut\u20082004; 53: 339\u201345.","DOI":"10.1136\/gut.2003.020107"},{"key":"2022061700295934200_B35","doi-asserted-by":"crossref","unstructured":"Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol\u20081999; 162: 5317\u201326.","DOI":"10.4049\/jimmunol.162.9.5317"},{"key":"2022061700295934200_B36","doi-asserted-by":"crossref","unstructured":"Ono M, Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1\/Runx1. Nature\u20082007; 446: 685\u20139.","DOI":"10.1038\/nature05673"},{"key":"2022061700295934200_B37","doi-asserted-by":"crossref","unstructured":"Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med\u20081996; 184: 387\u201396.","DOI":"10.1084\/jem.184.2.387"},{"key":"2022061700295934200_B38","doi-asserted-by":"crossref","unstructured":"Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun\u20081996; 9: 211\u201320.","DOI":"10.1006\/jaut.1996.0026"},{"key":"2022061700295934200_B39","doi-asserted-by":"crossref","unstructured":"Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev\u20082006; 212: 8\u201327.","DOI":"10.1111\/j.0105-2896.2006.00427.x"},{"key":"2022061700295934200_B40","doi-asserted-by":"crossref","unstructured":"Rouse BT. Regulatory T cells in health and disease. J Intern Med\u20082007; 262: 78\u201395.","DOI":"10.1111\/j.1365-2796.2007.01836.x"},{"key":"2022061700295934200_B41","doi-asserted-by":"crossref","unstructured":"Taylor MD, Harris A, Babayan SA, et al. CTLA-4 and CD4+ CD25+ regulatory T cells inhibit protective immunity to filarial parasites in vivo. J Immunol\u20082007; 179: 4626\u201334.","DOI":"10.4049\/jimmunol.179.7.4626"},{"key":"2022061700295934200_B42","doi-asserted-by":"crossref","unstructured":"Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol\u20082007; 178: 2155\u201362.","DOI":"10.4049\/jimmunol.178.4.2155"},{"key":"2022061700295934200_B43","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res\u20082003; 9: 606\u201312."},{"key":"2022061700295934200_B44","doi-asserted-by":"crossref","unstructured":"Chaput N, Darrasse-Jeze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol\u20082007; 179: 4969\u201378.","DOI":"10.4049\/jimmunol.179.8.4969"},{"key":"2022061700295934200_B45","doi-asserted-by":"crossref","unstructured":"Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol\u20082006; 13: 1252\u20138.","DOI":"10.1245\/s10434-006-9015-y"},{"key":"2022061700295934200_B46","doi-asserted-by":"crossref","unstructured":"El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg\u20082006; 105: 430\u20137.","DOI":"10.3171\/jns.2006.105.3.430"},{"key":"2022061700295934200_B47","doi-asserted-by":"crossref","unstructured":"Yoshimura K, Laird LS, Chia CY, et al. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res\u20082007; 67: 10058\u201366.","DOI":"10.1158\/0008-5472.CAN-07-0573"},{"key":"2022061700295934200_B48","doi-asserted-by":"crossref","unstructured":"Boyman O, Surh CD, Sprent J. Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther\u20082006; 6: 1323\u201331.","DOI":"10.1517\/14712598.6.12.1323"},{"key":"2022061700295934200_B49","doi-asserted-by":"crossref","unstructured":"de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol\u20082004; 34: 2480\u20138.","DOI":"10.1002\/eji.200425274"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/23\/9875\/2592853\/9875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/23\/9875\/2592853\/9875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T21:12:00Z","timestamp":1684703520000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/23\/9875\/540745\/Overcoming-Immunoescape-Mechanisms-of-BCL1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":49,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2008,12,1]]},"published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-1979","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}